MTC 1203

Drug Profile

MTC 1203

Alternative Names: MTC-1203

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer Mitoconix Bio
  • Class Neuroprotectants; Peptides
  • Mechanism of Action Mitochondrial protein inhibitors; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Huntington's disease; Neurodegenerative disorders

Most Recent Events

  • 04 Jul 2017 Preclinical trials in Huntington's disease in Israel before July 2017 (FutuRx website, July 2017)
  • 04 Jul 2017 Preclinical trials in Neurodegenerative disorders in Israel before July 2017 (FutuRx website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top